FIELD: medicine.
SUBSTANCE: group of inventions is intended for treatment of inflammatory immune diseases mediated by T-cells, or of allergic diseases mediated by T-cells. The patient in need of treatment receives an effective amount of N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-[(1S)-1-methylpropyl]-6-[6-(1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide or a pharmaceutically acceptable salt thereof.
EFFECT: group of inventions allows to provide higher clinical effectiveness.
8 cl, 3 dwg, 1 tbl, 373 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | 2012 |
|
RU2632193C2 |
| INDANONE DERIVATIVE, ITS PHARMACEUTICALLY ACCEPTABLE SALT OR ENANTIOMER, METHOD FOR PRODUCING IT AND PHARMACEUTICAL COMPOSITION CONTAINING IT AND APPLICABLE FOR PREVENTING OR TREATING VIRAL DISEASE | 2012 |
|
RU2574591C2 |
| 1,3-BENZODIOXOLE DERIVATIVE | 2015 |
|
RU2679131C2 |
| SUBSTITUTED BENZENE COMPOUNDS | 2012 |
|
RU2629118C2 |
| NOVEL CONDENSED PYRIDINE DERIVATIVES USED AS C-MET TYROSINE KINASE INHIBITORS | 2013 |
|
RU2619130C2 |
| BICYCLIC LACTAMS AND METHODS FOR USE THEREOF | 2016 |
|
RU2716136C2 |
| AMIDES OF CONDENSED PIPERIDINE AS MODULATORS OF ION CHANNELS | 2014 |
|
RU2741810C2 |
| SUBSTITUTED BENZENE COMPOUNDS | 2013 |
|
RU2658919C2 |
| PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | 2011 |
|
RU2617405C2 |
| HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | 2018 |
|
RU2797822C2 |
